Thangirala Sudha1, Dhruba J Bharali1, Murat Yalcin1,2, Noureldien He Darwish1,3, Melis Debreli Coskun1,4, Kelly A Keating1, Hung-Yun Lin5,6, Paul J Davis1,7, Shaker A Mousa1. 1. Pharmaceutical Research Institute, Albany College of Pharmacy & Health Sciences, Rensselaer, NY 12144, USA. 2. Department of Physiology, Faculty of Veterinary Medicine, Uludag University, Gorukle, 16059 Bursa, Turkey. 3. Clinical Pathology Department, Hematology Unit, Faculty of Medicine, Mansoura University, Dakahliya 35516, Egypt. 4. Department of Biology, Faculty of Arts & Sciences, Uludag University, Gorukle, 16059 Bursa, Turkey. 5. PhD Program for Cancer Biology and Drug Discovery, College of Medical Science & Technology, Taipei Medical University, Taipei 11031, Taiwan. 6. Taipei Cancer Center, Taipei Medical University, Taipei 11031, Taiwan. 7. Department of Medicine, Albany Medical College, Albany, NY, 12208, USA.
Abstract
AIM: Nano-diamino-tetrac (NDAT) targets a receptor on integrin αvβ3; αvβ3 is generously expressed by cancer cells and dividing endothelial cells and to a small extent by nonmalignant cells. The tetrac (tetraiodothyroacetic acid) of NDAT is covalently bound to a poly(lactic-co-glycolic acid) nanoparticle that encapsulates anticancer drugs. We report NDAT delivery efficiency of cisplatin to agent-susceptible urinary bladder cancer xenografts. MATERIALS & METHODS: Cisplatin-loaded NDAT (NDAT-cisplatin) was administered to xenograft-bearing nude mice. Tumor size response and drug content were measured. RESULTS: Intratumoral drug concentration was up to fivefold higher (p < 0.001) in NDAT-cisplatin-exposed lesions than with conventional systemic administration. Tumor volume reduction achieved was NDAT-cisplatin > NDAT without cisplatin > cisplatin alone. CONCLUSION: NDAT markedly enhances cisplatin delivery to urinary bladder cancer xenografts and increases drug efficacy.
AIM: Nano-diamino-tetrac (NDAT) targets a receptor on integrin αvβ3; αvβ3 is generously expressed by cancer cells and dividing endothelial cells and to a small extent by nonmalignant cells. The tetrac (tetraiodothyroacetic acid) of NDAT is covalently bound to a poly(lactic-co-glycolic acid) nanoparticle that encapsulates anticancer drugs. We report NDAT delivery efficiency of cisplatin to agent-susceptible urinary bladder cancer xenografts. MATERIALS & METHODS:Cisplatin-loaded NDAT (NDAT-cisplatin) was administered to xenograft-bearing nude mice. Tumor size response and drug content were measured. RESULTS: Intratumoral drug concentration was up to fivefold higher (p < 0.001) in NDAT-cisplatin-exposed lesions than with conventional systemic administration. Tumor volume reduction achieved was NDAT-cisplatin > NDAT without cisplatin > cisplatin alone. CONCLUSION: NDAT markedly enhances cisplatin delivery to urinary bladder cancer xenografts and increases drug efficacy.
Authors: Thangirala Sudha; Dhruba J Bharali; Murat Yalcin; Noureldien He Darwish; Melis Debreli Coskun; Kelly A Keating; Hung-Yun Lin; Paul J Davis; Shaker A Mousa Journal: Int J Nanomedicine Date: 2017-02-15